Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC ...

This study provides compelling evidence that SLC7A11 may serve as a potential therapeutic target for trastuzumab-resistant HER2-positive breast cancer. While the findings are well-supported by robust ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined ... compounds in development that leverage different mechanisms of ...

Source Reference: Tolaney S, et al "Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically ...

Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) combined with Perjeta (pertuzumab) as first-line treatment improved progression-free survival (PFS) versus standard care for patients with ...

1,157 total patients, 770 of whom were randomized to receive either trastuzumab deruxtecan with pertuzumab (383 patients) or the current standard of care (387 patients). Main Takeaway First-line ...